Access! 2020 - Missed the early-bird? Save $300 off full-pass registration when you register by March 27

Generic Savings by Condition: The Latest Data

When patients and providers opt for generic and biosimilar alternatives instead of brand-name prescription and biologic medications, the savings really add up—for any condition being treated.

Read Blog
Just Released: AAM White Paper

New report by AAM finds health plans in the Medicare program and the commercial market are delaying patient access to new lower-priced generic competitors. #DoesntAddUp

Learn More
#DoesntAddUp

If generic prescription drug prices are falling each year, why are consumer costs for prescription drugs rising?

Take Action
Access! 2020 Keynote Speaker Announced

Chris Wallace, respected veteran newsman and host of Fox News Sunday, will speak at Access! 2020. Join us to hear a unique perspective on the industry.

View Agenda
Give IPR the Green Light

IPR (Inter Partes Review) works. It expedites the pathway for generic and biosimilar medicines to come to market and it rewards true innovation. It's time for Congress to take action to enhance the PTO's IPR authority.

Read Blog
New Analysis of the BLOCKING Act

New report from Matrix Global Advisors finds the delay of just one generic medicine will increase prescription drug costs for patients by $1.7 billion.

View Press Release
The Case for Competition

Now available: AAM's full 2019 Generic Drug & Biosimilars Access & Savings in the U.S. Report

Read Full Report

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of current drugs and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Feb 25, 2020 | Sara Skubikowski

Savings by Condition: The Latest Data

Feb 24, 2020 | Rachel Schwartz

AAM and the Biosimilars Council Applaud FDA’s Release of Enhanced Purple Book

Feb 20, 2020 | Craig Burton

White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients

Feb 20, 2020 | Rachel Schwartz

Insurers Fail to Get New Generics to America’s Patients

2020 Avalere Analysis Generic Tiers

Feb 13, 2020 | Rachel Schwartz

Avalere Analysis Finds Medicare Part D Patients Are Paying More For Their Lower-Cost Generics

Feb 10, 2020 | Rachel Schwartz

AAM Statement on Resignation of Chip Davis